Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany Northwest Biotherapeutics announced that it has initiated the Phase III trial of DCVax-L in Germany. The first site to open in Germany was a medical center in Dresden, which was initiated in late May. The Company has now scheduled the full-day site initiations for 3 more sites during June and 4 further sites in July.
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.